Conference brings together families affected by NPC from across the US
ALACHUA, Fla., June 27, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB:CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the company has been invited to present on its clinical trials at the annual gathering of families and physicians of the National Niemann-Pick Disease Foundation. The conference will take place at the Hyatt Regency Hotel, Louisville, Kentucky between August 2 and 4, 2018. Niemann-Pick Disease Type C (NPC) is a rare genetic disease that causes neurologic, liver, lung and other organ dysfunction and is ultimately fatal.
“We look forward to providing an update to the NPC community on our clinical trials, and to hearing directly from those most affected by NPC – the patients and their families,” said N. Scott Fine, Chairman and CEO of CTD Holdings.
CTD will be represented at the conference by Sharon Hrynkow, Ph.D., Senior Vice President for Medical Affairs and Co-Chair of CTD’s Scientific Advisory Board, and Caroline Hastings, MD, Pediatric Hematologist Oncologist at the UCSF Benioff Children’s Hospital Oakland and Co-PI of the Phase I clinical trial, “A Phase I Study to Evaluate the Single and Multiple-dose Pharmacokinetics of Intravenous Trappsol® Cyclo™ (HPBCD) in Patients with Niemann-Pick Disease Type C (NPC-1) and the Effects of Dosing upon Biomarkers of NPC Disease”, (NCT 02939547).
Dr. Hastings serves on CTD’s Scientific Advisory Board and is the Senior Clinical Advisor to CTD’s Phase I/II study, “A Phase I/II Study to Evaluate the Safety and pK of IV Trappsol® Cyclo™ (HPBCD) in Patients with Niemann-Pick Disease Type C (NPC-1) and the Pharmacodynamic Effects of Treatment upon Markers of Cholesterol Metabolism and Clinical Outcomes” (NCT02912793), now underway in Europe and Israel. Both trials are evaluating CTD’s proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™, administered intravenously.
Date: Friday, August 3rd
Time: Afternoon Session
Location: Hyatt Regency Hotel, Louisville, KY
CTD’s Family Liaisons will also join the conference: Shannon Reedy (email@example.com), from the US, and Jackie Imrie (firstname.lastname@example.org), from the UK. Both will be available before, during and after the conference to discuss the features of CTD’s clinical trials with NPC patients and their families. Families may also be in touch with Dr. Hastings (email@example.com) directly. Physicians who wish to know more about the clinical trials may contact: Dr. Hrynkow (Sharon.Hrynkow@cyclodex.com); Dr. Hastings for the Phase I study; or Dr. Reena Sharma, Coordinating Investigator for the Phase I/II trial (Reena.Sharma@srft.nhs.uk).
About CTD Holdings:
CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease, on a compassionate use basis and is the subject of two ongoing clinical trials. Additional indications for the active ingredient in Trappsol® Cyclo™, are in development. For additional information, visit the company’s website: www.ctd-holdings.com
Safe Harbor Statement:
This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Sitrick and Company
(212) 573-6100, Ext. 395